Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferonγ (IFN-γ) are recognised by T cells while resisting destruction by natural killer (NK) cells

The inoculation into mice of genetically engineered tumour cells that secrete IL-2 or IFNγ results in rejection, while unmodified parental tumour cells grow progressively. In vivo studies demonstrated synergy between IL-2 and IFNγ leading to the rejection of the transduced tumour cells. IL-2 is requ...

Ausführliche Beschreibung